Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C

Maribel Rodriguez-Torres, Lennox J. Jeffers, Muhammad Y. Sheikh, Lorenzo Rossaro, Victor Ankoma-Sey, Fayez M. Hamzeh, Paul Martin

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49% vs. 34%, P<0.001). The absence of HCV RNA in serum was more frequent in non-Latino whites at week 4 (P = 0.045) and throughout the treatment period (P<0.001 for all other comparisons). Latino or non-Latino background was an independent predictor of the rate of sustained virologic response in an analysis adjusted for baseline differences in BMI, cirrhosis, and other characteristics. Adherence to treatment did not differ significantly between the two groups. The numbers of patients with adverse events and dose modifications were similar in the two groups, but fewer Latino patients discontinued therapy because of adverse events. CONCLUSIONS: Treatment with peginterferon alfa-2a and ribavirin for 48 weeks resulted in rates of sustained virologic response among patients infected with HCV genotype 1 that were lower among Latino whites than among non-Latino whites. Strategies to improve the sustained virologic response in Latinos are needed. (ClinicalTrials.gov number, NCT00107653.).

Original languageEnglish (US)
Pages (from-to)257-267
Number of pages11
JournalNew England Journal of Medicine
Volume360
Issue number3
DOIs
StatePublished - Jan 15 2009

Fingerprint

Ribavirin
Hepatitis C
Hispanic Americans
Hepacivirus
Virus Diseases
peginterferon alfa-2a
Fibrosis
Therapeutics
Genotype
Ethnic Groups
Body Mass Index
Language
Parents
Sustained Virologic Response
Clinical Trials
Prospective Studies
RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rodriguez-Torres, M., Jeffers, L. J., Sheikh, M. Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F. M., & Martin, P. (2009). Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C. New England Journal of Medicine, 360(3), 257-267. https://doi.org/10.1056/NEJMoa0805062

Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C. / Rodriguez-Torres, Maribel; Jeffers, Lennox J.; Sheikh, Muhammad Y.; Rossaro, Lorenzo; Ankoma-Sey, Victor; Hamzeh, Fayez M.; Martin, Paul.

In: New England Journal of Medicine, Vol. 360, No. 3, 15.01.2009, p. 257-267.

Research output: Contribution to journalArticle

Rodriguez-Torres, M, Jeffers, LJ, Sheikh, MY, Rossaro, L, Ankoma-Sey, V, Hamzeh, FM & Martin, P 2009, 'Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C', New England Journal of Medicine, vol. 360, no. 3, pp. 257-267. https://doi.org/10.1056/NEJMoa0805062
Rodriguez-Torres, Maribel ; Jeffers, Lennox J. ; Sheikh, Muhammad Y. ; Rossaro, Lorenzo ; Ankoma-Sey, Victor ; Hamzeh, Fayez M. ; Martin, Paul. / Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C. In: New England Journal of Medicine. 2009 ; Vol. 360, No. 3. pp. 257-267.
@article{b11539a7cbfa40ad948f4b4cca0e5b5f,
title = "Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C",
abstract = "BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49{\%} vs. 34{\%}, P<0.001). The absence of HCV RNA in serum was more frequent in non-Latino whites at week 4 (P = 0.045) and throughout the treatment period (P<0.001 for all other comparisons). Latino or non-Latino background was an independent predictor of the rate of sustained virologic response in an analysis adjusted for baseline differences in BMI, cirrhosis, and other characteristics. Adherence to treatment did not differ significantly between the two groups. The numbers of patients with adverse events and dose modifications were similar in the two groups, but fewer Latino patients discontinued therapy because of adverse events. CONCLUSIONS: Treatment with peginterferon alfa-2a and ribavirin for 48 weeks resulted in rates of sustained virologic response among patients infected with HCV genotype 1 that were lower among Latino whites than among non-Latino whites. Strategies to improve the sustained virologic response in Latinos are needed. (ClinicalTrials.gov number, NCT00107653.).",
author = "Maribel Rodriguez-Torres and Jeffers, {Lennox J.} and Sheikh, {Muhammad Y.} and Lorenzo Rossaro and Victor Ankoma-Sey and Hamzeh, {Fayez M.} and Paul Martin",
year = "2009",
month = "1",
day = "15",
doi = "10.1056/NEJMoa0805062",
language = "English (US)",
volume = "360",
pages = "257--267",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "3",

}

TY - JOUR

T1 - Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C

AU - Rodriguez-Torres, Maribel

AU - Jeffers, Lennox J.

AU - Sheikh, Muhammad Y.

AU - Rossaro, Lorenzo

AU - Ankoma-Sey, Victor

AU - Hamzeh, Fayez M.

AU - Martin, Paul

PY - 2009/1/15

Y1 - 2009/1/15

N2 - BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49% vs. 34%, P<0.001). The absence of HCV RNA in serum was more frequent in non-Latino whites at week 4 (P = 0.045) and throughout the treatment period (P<0.001 for all other comparisons). Latino or non-Latino background was an independent predictor of the rate of sustained virologic response in an analysis adjusted for baseline differences in BMI, cirrhosis, and other characteristics. Adherence to treatment did not differ significantly between the two groups. The numbers of patients with adverse events and dose modifications were similar in the two groups, but fewer Latino patients discontinued therapy because of adverse events. CONCLUSIONS: Treatment with peginterferon alfa-2a and ribavirin for 48 weeks resulted in rates of sustained virologic response among patients infected with HCV genotype 1 that were lower among Latino whites than among non-Latino whites. Strategies to improve the sustained virologic response in Latinos are needed. (ClinicalTrials.gov number, NCT00107653.).

AB - BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49% vs. 34%, P<0.001). The absence of HCV RNA in serum was more frequent in non-Latino whites at week 4 (P = 0.045) and throughout the treatment period (P<0.001 for all other comparisons). Latino or non-Latino background was an independent predictor of the rate of sustained virologic response in an analysis adjusted for baseline differences in BMI, cirrhosis, and other characteristics. Adherence to treatment did not differ significantly between the two groups. The numbers of patients with adverse events and dose modifications were similar in the two groups, but fewer Latino patients discontinued therapy because of adverse events. CONCLUSIONS: Treatment with peginterferon alfa-2a and ribavirin for 48 weeks resulted in rates of sustained virologic response among patients infected with HCV genotype 1 that were lower among Latino whites than among non-Latino whites. Strategies to improve the sustained virologic response in Latinos are needed. (ClinicalTrials.gov number, NCT00107653.).

UR - http://www.scopus.com/inward/record.url?scp=58349122475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58349122475&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0805062

DO - 10.1056/NEJMoa0805062

M3 - Article

VL - 360

SP - 257

EP - 267

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 3

ER -